<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580372</url>
  </required_header>
  <id_info>
    <org_study_id>01332</org_study_id>
    <nct_id>NCT00580372</nct_id>
  </id_info>
  <brief_title>UARK 89-001 Phase II Study of Intensive &quot;TOTAL THERAPY&quot; For Untreated or Minimally Treated Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Intensive &quot;TOTAL THERAPY&quot; for Untreated or Minimally Treated Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This experimental study evaluates the effects of a series of intensive drug regimens as
      initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4─6 months
      apart in support of high─dose Melphalan, followed by Interferon treatment indefinitely.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAD</intervention_name>
    <description>3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-Dose cyclophosphamide</intervention_name>
    <description>Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemopoietic stem cell procurement</intervention_name>
    <description>Collection target = 10 x 10^6 cells/kg</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDAP</intervention_name>
    <description>Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hemopoietic Stem Cell Transplant 1</intervention_name>
    <description>4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hemopoietic Stem Cell Transplant 2</intervention_name>
    <description>4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance</intervention_name>
    <description>3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated patients with the diagnosis of multiple myeloma are eligible.
             Similarly, patients who have not had more than one cycle of standard chemotherapy or
             up to one month of interferon and/or glucocorticoids are eligible.

          -  Patients must have objective evidence of, or be symptomatic from, complications due to
             myeloma (e.g., bone pain from fractures, weakness from anemia). Asymptomatic patients
             may be treated only if the diagnosis is confirmed and if there is evidence of
             increasing tumor mass (e.g., rising myeloma protein and/or increasing lytic lesions).

          -  Asymptomatic patients with idiopathic monoclonal peaks, localized plasmacytomas, or
             indolent, asymptomatic myeloma are not eligible for this study. Any patient without
             documented increasing disease and/or clearly symptomatic disease is not eligible.

          -  Measurable, direct manifestations of myeloma must be present, such as monoclonal serum
             or urine globulins. Plasma cell tumors must also be documented. Patients without
             protein criteria are eligible if bone marrow has &gt; 30% plasmacytosis documented by
             bilateral bone marrow aspirations and biopsies.

          -  Patients with all stages of multiple myeloma (I, II, III) are eligible. Necessary
             baseline studies must be obtained to determine the stage prior to registration.

          -  Patients may have received local radiation to painful compression fractures or lytic
             bone lesions, provided that adequate autologous bone marrow can still be harvested.
             Patients presenting with clinical conditions requiring radiotherapy (e.g. spinal cord
             compression) may proceed with concurrent local radiation and VAD. Should compression
             fractures of known prestudy lytic lesions occur during later, more myelosuppressive
             phases of induction therapy, radiotherapy should be completed first prior to
             proceeding with high-dose cyclophosphamide, EDAP or melphalan.

          -  Patients should be older than 15 years of age and may be up to 65 years old.

          -  Pregnant females are excluded from study.

          -  Eligibility criteria change with the progress through the different phases of the
             induction program towards the two cycles of marrow-ablative therapy. These are
             summarized in the eligibility checklist.

          -  Briefly, prior to VAD, patients must have a normal cardiac ejection fraction of &gt; 50%
             (on ECHO cardiography or MUGGA scan), and fairly normal liver function tests
             (bilirubin &lt; 2 mg% and serum transaminase levels less than 2 x normal). Screening for
             viral hepatitis should be negative for acute or chronic active hepatitis. Positive
             antibody (anti-HAV, HBSAb) suggestive of remote exposure is acceptable. However,
             patients who test positive for Hepatitis C antibody (anti-HCV) or HIV are ineligible.
             Those with renal failure are eligible and should start VAD promptly and receive
             additional medical measures as needed. Patients presenting with infections upon
             presentation shall receive proper medical management prior to starting therapy.
             Patient's performance status is not a criterion for entry on the VAD portion of this
             program.

          -  After 2 or 3 cycles of VAD, serum creatinine levels must be 2 mg% and carbon monoxide
             diffusion capacity 50%. Cardiac and liver function requirements as with VAD.

          -  Not until reaching the high-dose melphalan stage of 70 mg/M2 will there be a
             requirement for Zubrod performance of 0 and 1 which must also be fulfilled with each
             of the 2 marrow-ablative doses of melphalan (200 mg/M2).

        Exclusion Criteria:

          -  Less than 10 x 108 cells/kg stored.

          -  a granulocyte count of less than 1500/µl and a platelet count less than 150,000/µl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>August 1, 2016</results_first_submitted>
  <results_first_submitted_qc>August 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
VAD: 3 Cycles (3rd cycle optional):
Vincristine 0.5 mg/d d 1 – 4 CI Adriamycin 10 mg/m2/d d 1 – 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 – 5 Mesna 3.6 g/m2 d 1
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
VAD: 3 Cycles (3rd cycle optional):
Vincristine 0.5 mg/d d 1 – 4 CI Adriamycin 10 mg/m2/d d 1 – 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 – 5 Mesna 3.6 g/m2 d 1
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" lower_limit="26.5" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</title>
        <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
VAD: 3 Cycles (3rd cycle optional):
Vincristine 0.5 mg/d d 1 – 4 CI Adriamycin 10 mg/m2/d d 1 – 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 – 5 Mesna 3.6 g/m2 d 1
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</title>
          <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
VAD: 3 Cycles (3rd cycle optional):
Vincristine 0.5 mg/d d 1 – 4 CI Adriamycin 10 mg/m2/d d 1 – 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 – 5 Mesna 3.6 g/m2 d 1
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Anemia Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Neutropeni Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>WBC Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thrombocyt Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 3</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 3</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 3</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 3</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 3</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory grade 3</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory grade 4</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bicarbonat grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 3</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 3</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 4</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypermagne grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 3</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 3</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary grade 3</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary grade 4</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 3</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 4</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia grade 2</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thrombocyt grade 2</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/ pancreas grade 1</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 2</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 1</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 2</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 1</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 2</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 1</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 2</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 1</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 2</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 1</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 2</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory grade 2</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bicarbonat grade 1</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 1</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 1</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 2</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 2</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypemagne grade 1</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 1</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 2</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 1</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 1</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 2</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 2</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/genitourinary grade 1</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary grade 2</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 1</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 2</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bart Barlogie</name_or_title>
      <organization>University of Arkansas for Medical Science</organization>
      <phone>501-526-2873</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

